Results 141 to 150 of about 9,785,178 (296)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Annual report, fiscal year 1984 : follow-up on audit recommendations.

, 1984
"A Report to the Kansas Legislature by the Legislative Post Audit Committee, state of Kansas."; "August 27, 1984."; Fiscal year ends June 30.Constitutes the annual report of the ...
Kansas. Legislative Post Audit Committee.
core   +1 more source

3D Simultaneous Post-contrast T1/T2 Mapping and Synthetic Multi-Contrast Late Gadolinium Enhancement at 0.55T: Validation in Porcine Myocardial Infarction Model. [PDF]

Invest Radiol
Si D, Varghese J, Littlewood SJ, Binzel K, Pervaiz S, Mergaye M, Khan M, Han Y, Kunze KP, Crabb MG, Simonetti OP, Prieto C, Botnar RM.   +12 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Annual report, fiscal year 1985 : follow-up report on audit recommendations.

, 1985
"A Report to the Kansas Legislature by the Legislative Post Audit Committee, state of Kansas."; "July 8, 1985."; Fiscal year ends June 30.Constitutes the annual report of the ...
Kansas. Legislative Post Audit Committee.
core   +1 more source

The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post-Operative Neuropathic and Non-Neuropathic Complications. [PDF]

Clin Obes
Thirumalai S, Balamurugan G, Jagdale S, Hussain K, Sayyadi L, Vasu SKA, Turner C, Abuawwad M.   +7 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Other title: Financial and Compliance Audit Reports provided by the Legislative Division of Post Audit, State of Kansas, 2016-2017

, 2016
application/pdf; "A Report to the Legislative Post Audit Committee"--Cover.A set of 4 Financial and Compliance Audit Reports provided by the the Legislative Division of Post Audit, State of Kansas.Financial and Compliance Audit Report : Kansas Lottery ...
Kansas. Legislature. Legislative Division of Post Audit.
core  

Deer Antler δ¹⁸O Records Desalination in Israel's Water Supply. [PDF]

Rapid Commun Mass Spectrom
Laposki C, Darcy A, Werner N, Hartman G.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source